The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
ApexOnco Front Page
Recent articles
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
The group is persevering with Granite, but funds might be hard to come by.
For $850m up front Roche gets to challenge Pfizer.
First-in-human trial initiations reveal four KRAS assets.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
